Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $304.41 and traded as low as $294.75. Genmab A/S shares last traded at $298.16, with a volume of 766 shares.
Genmab A/S Stock Performance
The firm has a 50 day moving average of $290.71 and a 200-day moving average of $304.41. The stock has a market capitalization of $19.49 billion, a PE ratio of 30.96 and a beta of 1.01.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last issued its earnings results on Wednesday, February 14th. The company reported $3.63 earnings per share for the quarter. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The company had revenue of $675.29 million for the quarter.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
- Five stocks we like better than Genmab A/S
- Most Volatile Stocks, What Investors Need to Know
- Here are the Pros and Cons of Using Options Call Debit Spreads
- Stock Sentiment Analysis: How it Works
- Carmax Returns to the Bargain Basement: Buy the Dip?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
